Simmons Bank Purchases 2,663 Shares of AstraZeneca PLC (NASDAQ:AZN)

Simmons Bank increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 7.3% during the third quarter, HoldingsChannel reports. The fund owned 39,074 shares of the company’s stock after buying an additional 2,663 shares during the quarter. Simmons Bank’s holdings in AstraZeneca were worth $3,044,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. McClarren Financial Advisors Inc. grew its position in shares of AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after buying an additional 247 shares during the last quarter. GHP Investment Advisors Inc. bought a new stake in shares of AstraZeneca in the 2nd quarter valued at about $26,000. Capital Performance Advisors LLP bought a new stake in shares of AstraZeneca in the 3rd quarter valued at about $28,000. Pathway Financial Advisers LLC bought a new stake in shares of AstraZeneca in the 1st quarter valued at about $29,000. Finally, Hobbs Group Advisors LLC bought a new stake in shares of AstraZeneca in the 2nd quarter valued at about $35,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.6 %

Shares of NASDAQ:AZN opened at $65.19 on Wednesday. The stock has a market cap of $202.13 billion, a price-to-earnings ratio of 31.49, a PEG ratio of 1.20 and a beta of 0.47. The business’s 50 day moving average is $76.20 and its 200 day moving average is $78.47. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on AZN. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, TD Cowen upped their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.